Andrew brings to JAZZ significant experience in venture capital, company building, technology development, and neurosurgery. He has served as founder, investor, director, and chairman of many successful companies. Prior to joining the firm, he was a general partner at Flare Capital. Previously, he was a venture partner at Sprout Group and a principal at Canaan Partners.
Andrew has led numerous venture capital investments and has helped many early stage companies become market leaders. He was a founder (and invented the core technology) of Northstar Neuroscience, which went public in 2006 (NASDAQ: NSTR) and was subsequently acquired by St. Jude Medical (NYSE: STJ). He also served as Chairman of IntElect Medical, which was acquired by Boston Scientific (NYSE: BSX). He currently serves as chairman of Functional Neuromodulation, a company developing brain stimulation therapy for Alzheimer’s disease.
Representative prior investments and board roles include BridgePoint Medical (acquired by Boston Scientific, NYSE: BSX), Explorys (acquired by IBM, NYSE: IBM), Functional Neuromodulation, Halo Neuroscience, i1 Biometrics, Predilytics (acquired by Welltok), SetPoint Medical, Spine Wave, Vertos Medical, and Visiogen (acquired by Abbott, NYSE: ABT).
During more than a decade in the healthcare profession as a neurosurgeon, he published more than 50 medical articles, wrote chapters for several medical textbooks, and was co-editor of a book about cerebrovascular surgery. His scientific work has been presented at many international conferences and he holds numerous patents for his inventions. As a board certified neurosurgeon, he served as clinical assistant professor of neurosurgery at the New York University School of Medicine. He currently serves on the Cornell Biomedical Engineering Advisory Council, the Advisory Council of the McGovern Center for Venture Development in Life Sciences at Cornell, and the Executive Board of the Yale Center for Biomedical and Interventional Technology. He has served on the Cornell University Council as chairman of the Technology Transfer Committee and member of the Life Sciences Advisory Board. He has also served as a member of the Innovation Advisory Board at the Cleveland Clinic.
Andrew earned his M.D. from Weill Cornell University Medical College and his M.B.A. from the University of Pittsburgh after studying neuroscience at Cornell (A.B.) and Oxford University.